Table 1.

Participant baseline clinical characteristics (PP)

Baseline characteristics	Etanercept (n=31)	Adalimumab (n=18)
Age Mean (SD)	52 (10.0)	52 (13.8)
Gender, Female n (%)	25 (81)	14 (78)
Caucasian n (%)	26 (84)	17 (94)
Disease duration (years) Mean (SD)	4.5 (6.5)	4.4 (5.4)
CCP+, n (%)	19 (61)	10 (56)
RF positive, n (%)	17 (55)	8 (44)
DAS Mean (SD)	5.2 (1.1)	5.4 (0.7)
MTX dose (mg) Mean (SD)	16.8 (4.0)	18.4 (3.5)
Swollen joints (of 28) Mean (SD)	9.5 (5.9)	9.6 (6.0)
Tender joints (of 28) Mean (SD)	12.6 (6.8)	12.9 (7.2)
CRP (mg/L) Mean (SD)	11.0 (25.9)	13.6 (25.0)